You are here
HAWAII BIOTECH, INC.
UEI: ECJKEEFL4L51
# of Employees: N/A
HUBZone Owned: No
Socially and Economically Disadvantaged: No
Woman Owned: No
Award Charts
Award Listing
-
RECOMBINANT WEST NILE VIRUS VACCINE ADJUVANTED WITH SLA-LSQ
Amount: $2,997,218.00The contract supports the development of TLR4 agonist within an oil-in-water emulsion as a vaccine adjuvant. The adjuvant development activities are being conducted within the context of vaccines to p ...
SBIRPhase II2022Department of Health and Human Services National Institutes of Health -
Chikungunya Recombinant Subunit Vaccine
Amount: $2,000,000.007. Project Summary/Abstract Chikungunya virus (CHIKV) is an alphavirus classified as a category C priority pathogen that causes fever, rash, and arthralgia in humans, leading to debilitating illness a ...
SBIRPhase II2020Department of Health and Human Services National Institutes of Health -
Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses
Amount: $3,090,424.00Project Summary/AbstractThe NIH/NIAID 2017 Strategic Plan is specifically directed at promoting research that can provide solutions to mitigate the threat posed by emerging and re-emerging diseases. T ...
SBIRPhase II2019Department of Health and Human Services National Institutes of Health -
Chikungunya Recombinant Subunit Vaccine
Amount: $600,000.00DESCRIPTION provided by applicant Chikungunya virus CHIKV is an alphavirus classified as a category C priority pathogen that causes fever rash and arthralgia in humans In the past decade CHI ...
SBIRPhase I2016Department of Health and Human Services National Institutes of Health -
Novel Adjuvants to Enhance the Immunogenicity of a Dengue Vaccine
Amount: $99,888.00Dengue virus (DENV) is a mosquito-borne flavivirus that poses a tremendous public health threat throughout the world. The U.S. military has also been challenged by dengue for over a hundred years and ...
SBIRPhase I2015Department of Defense Army -
Cross-Protective Multivalent Vaccine for Tick-Borne Flaviviruses
Amount: $2,113,306.00DESCRIPTION provided by applicant The tick borne flavivirus TBFV group includes a number of important human pathogens that result in serious encephalitic or hemorrhagic diseases that are either ...
SBIRPhase II2015Department of Health and Human Services National Institutes of Health -
Development of a Recombinant Subunit Vaccine for CCHF
Amount: $530,899.00DESCRIPTION (provided by applicant): Emerging and reemerging infectious diseases continue to pose serious health threats world-wide. Consequently, the development of measures to mitigate the natural, ...
SBIRPhase I2012Department of Health and Human Services National Institutes of Health -
Recombinant Subunit Vaccine For Tick-Borne Encephalitis
Amount: $2,983,510.00DESCRIPTION (provided by applicant): Tick-borne encephalitis (TBE) is a neurological disease caused by Flaviviruses of the tick-borne encephalitis group and causes death in up to 60% of the individua ...
SBIRPhase II2009Department of Health and Human Services National Institutes of Health -
Discovery of West Nile Virus Protease Inhibitors
Amount: $999,975.00DESCRIPTION (provided by applicant): The strain of West Nile virus now endemic in the continental United States is more virulent than the virus originally isolated in Africa and is classified as a cat ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health -
Structure Based Design of Dengue Virus Fusion Inhibitors
Amount: $797,650.00DESCRIPTION (provided by applicant): Over half of the world population is at risk for infection by dengue virus, a mosquito borne member of the Flavivirus family that consists of four distinct serotyp ...
SBIRPhase I2006Department of Health and Human Services National Institutes of Health
